Literature DB >> 8764060

Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages.

G Alkhatib1, C C Broder, E A Berger.   

Abstract

Work in this laboratory previously demonstrated that the tropism of different human immunodeficiency type 1 isolates for infection of human CD4+ continuous cell lines (e.g., T-cell lines and HeLa-CD4 transformants) versus primary macrophages is associated with parallel intrinsic fusogenic specificities of the corresponding envelope glycoproteins (Envs). For T-cell line-tropic isolates, it is well established that the target cell must also contain a human-specific fusion cofactor(s) whose identity is unknown. In this study, we tested the hypothesis that the Env fusion specificities underlying T-cell line versus macrophage tropism are determined by distinct cell type-specific fusion cofactors. We applied a recombinant vaccinia virus-based reporter gene assay for Env-CD4-mediated cell fusion; the LAV and Ba-L Envs served as prototypes for T-cell line-tropic and macrophage-tropic isolates, respectively. We examined CD4+ promyeloctic and monocytic cell lines that are infectible by T-cell line-tropic isolates and become susceptible to macrophage-tropic strains only after treatment with differentiating agents. We observed parallel changes in fusion specificity: untreated cells supported fusion by the LAV but not the Ba-L Env, whereas cells treated with differentiating agents acquired fusion competence for Ba-L. These results suggest that in untreated cells, the block to infection by macrophage-tropic isolates is at the level of membrane fusion; furthermore, the differential regulation of fusion permissiveness for the two classes of Envs is consistent with the existence of distinct fusion cofactors. To test this notion directly, we conducted experiments with transient cell hybrids formed between CD4-expressing nonhuman cells (murine NIH 3T3) and different human cell types. Hybrids formed with HeLa cells supported fusion by the LAV Env but not by the Ba-L Env, whereas hybrids formed with primary macrophages showed the opposite specificity; hybrids formed between HeLa cells and macrophages supported fusion by both Envs. These results suggest the existence of cell type-specific fusion cofactors selective for each type of Env, rather than fusion inhibitors for discordant Env-cell combinations. Finally, analyses based on recombinant protein expression and antibody blocking did not support the proposals by others that the CD44 or CD26 antigens are involved directly in the entry of macrophage-tropic isolates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764060      PMCID: PMC190506     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Product review. New mammalian expression vectors.

Authors:  B Moss; O Elroy-Stein; T Mizukami; W A Alexander; T R Fuerst
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

3.  Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.

Authors:  P A Ashorn; E A Berger; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.

Authors:  W A O'Brien; Y Koyanagi; A Namazie; J Q Zhao; A Diagne; K Idler; J A Zack; I S Chen
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

5.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family.

Authors:  I Stamenkovic; M Amiot; J M Pesando; B Seed
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

6.  Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation.

Authors:  A J Cann; J A Zack; A S Go; S J Arrigo; Y Koyanagi; P L Green; Y Koyanagi; S Pang; I S Chen
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.

Authors:  C Cheng-Mayer; M Quiroga; J W Tung; D Dina; J A Levy
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Differentiating agents facilitate infection of myeloid leukemia cell lines by monocytotropic HIV-1 strains.

Authors:  K Kitano; G C Baldwin; M A Raines; D W Golde
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

9.  Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system.

Authors:  O Elroy-Stein; T R Fuerst; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more
  55 in total

1.  The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.

Authors:  A D Sullivan; J Wigginton; D Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.

Authors:  P Steinberger; J Andris-Widhopf; B Bühler; B E Torbett; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes.

Authors:  M A Montano; V A Novitsky; J T Blackard; N L Cho; D A Katzenstein; M Essex
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.

Authors:  Navid Madani; Amy M Hubicki; Ana Luisa Perdigoto; Martin Springer; Joseph Sodroski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 8.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

9.  A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway.

Authors:  A Bonavia; B T Bullock; K M Gisselman; B J Margulies; J E Clements
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

10.  Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities.

Authors:  C Guillon; M E van der Ende; P H Boers; R A Gruters; M Schutten; A D Osterhaus
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.